Identification of Coronary Morphological Damage in Patients with Chronic Inflammatory Rheumatic Diseases
Abstract
:1. Introduction
2. Patients and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Castañeda, S.; Nurmohamed, M.T.; González-Gay, M.A. Cardiovascular disease in inflammatory rheumatic diseases. Best Pract. Res. Clin. Rheumatol. 2016, 30, 851–869. [Google Scholar] [CrossRef] [PubMed]
- Drosos, A.A.; Venetsanopoulou, A.A.; Pelechas, E.; Voulgari, P.V. Exploring Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis. Eur. J. Intern. Med. 2024, 128, 1–9. [Google Scholar] [CrossRef] [PubMed]
- Akhtari, S.; Harvey, P.J.; Eder, L. Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart. Am. J. Hypertens. 2024, 37, 933–942. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Szekanecz, Z.; Kerekes, G.; Dér, H.; Sándor, Z.; Szabó, Z.; Végvári, A.; Simkovics, E.; Soós, L.; Szentpétery, Á.; Besenyei, T.; et al. Accelerated atherosclerosis in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 2007, 1108, 349–358. [Google Scholar] [CrossRef] [PubMed]
- Reiss, A.B.; Silverman, A.; Khalfan, M.; Vernice, N.A.; Kasselman, L.J.; Carsons, S.E.; De Leon, J. Accelerated Atherosclerosis in Rheumatoid Arthritis: Mechanisms and Treatment. Curr. Pharm. Des. 2019, 25, 969–986. [Google Scholar] [CrossRef] [PubMed]
- Sanghavi, N.M.; Ingrassia, J.P.; Korem, S.; Ash, J.; Pan, S.; Wasserman, A. Cardiovascular Manifestations in Rheumatoid Arthritis. Cardiol. Rev. 2024, 32, 146–152. [Google Scholar] [CrossRef] [PubMed]
- Raj, R.; Thomas, S.; Gorantla, V. Accelerated atherosclerosis in rheumatoid arthritis: A systematic review. F1000Research 2022, 11, 466. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Łosińska, K.; Korkosz, M.; Kwaśny-Krochin, B. Endothelial dysfunction in patients with ankylosing spondylitis. Rheumatology 2019, 57, 100–105. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Bhattad, P.B.; Kulkarni, M.; Patel, P.D.; Roumia, M. Cardiovascular Morbidity in Ankylosing Spondylitis: A Focus on Inflammatory Cardiac Disease. Cureus 2022, 14, e25633. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Markov, M.; Georgiev, T.; Angelov, A.K.; Dimova, M. Adhesion molecules and atherosclerosis in ankylosing spondylitis: Implications for cardiovascular risk. Rheumatol. Int. 2024, 44, 1837–1848. [Google Scholar] [CrossRef] [PubMed]
- Giollo, A.; Dalbeni, A.; Cioffi, G.; Ognibeni, F.; Gatti, D.; Idolazzi, L.; Orsolini, G.; Minuz, P.; Rossini, M.; Fava, C.; et al. Factors associated with accelerated subclinical atherosclerosis in patients with spondyloarthritis without overt cardiovascular disease. Clin. Rheumatol. 2017, 36, 2487–2495. [Google Scholar] [CrossRef] [PubMed]
- Zhu, T.Y.; Li, E.K.; Tam, L.-S. Cardiovascular risk in patients with psoriatic arthritis. Int. J. Rheumatol. 2012, 2012, 714321. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Eder, L.; Thavaneswaran, A.; Chandran, V.; Cook, R.; Gladman, D.D. Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. Ann. Rheum. Dis. 2015, 74, 1830–1835. [Google Scholar] [CrossRef] [PubMed]
- Ramonda, R.; Nigro, A.L.; Modesti, V.; Nalotto, L.; Musacchio, E.; Iaccarino, L.; Punzi, L.; Doria, A. Atherosclerosis in psoriatic arthritis. Autoimmun. Rev. 2011, 10, 773–778. [Google Scholar] [CrossRef] [PubMed]
- Weber, B.N.; Giles, J.T.; Liao, K.P. Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease. Nat. Rev. Rheumatol. 2023, 19, 417–428. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Gonzalez-Juanatey, C.; Testa, A.; Garcia-Castelo, A.; Garcia-Porrua, C.; Llorca, J.; Vidan, J.; Hajeer, A.H.; Ollier, W.E.; Mattey, D.L.; Gonzalez-Gay, M.A. HLA-DRB1 statusaffectsendothelial function in treated patients with rheumatoid arthritis. Am. J. Med. 2003, 114, 647–652. [Google Scholar] [CrossRef] [PubMed]
- Végh, E.; Kerekes, G.; Pusztai, A.; Hamar, A.; Szamosi, S.; Váncsa, A.; Bodoki, L.; Pogácsás, L.; Balázs, F.; Hodosi, K.; et al. Effects of 1-year anti-TNF-α therapy on vascular function in rheumatoid arthritis and ankylosing spondylitis. Rheumatol. Int. 2020, 40, 427–436. [Google Scholar] [CrossRef] [PubMed]
- Kaleta, K.; Krupa, J.; Suchy, W.; Sopel, A.; Korkosz, M.; Nowakowski, J. Endothelial dysfunction and risk factors for atherosclerosis in psoriatic arthritis: Overview and comparison with rheumatoid arthritis. Rheumatol. Int. 2024, 44, 1587–1606. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Avouac, J.; Ait-Oufella, H.; Habauzit, C.; Benkhalifa, S.; Combe, B. The Cardiovascular Safety of Tumour Necrosis Factor Inhibitors in Arthritic Conditions: A Structured Review with Recommendations. Rheumatol. Ther. 2025, 12, 211–236. [Google Scholar] [CrossRef] [PubMed]
- Murdaca, G.; Colombo, B.M.; Cagnati, P.; Gulli, R.; Spanò, F.; Puppo, F. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012, 224, 309–317. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Juanatey, C.; Llorca, J.; Testa, A.; Revuelta, J.; Garcia-Porrua, C.; Gonzalez-Gay, M.A. Increased prevalence of severe subclinical atherosclerotic findings in long-term treated rheumatoid arthritis patients without clinically evident atherosclerotic disease. Medicine 2003, 82, 407–413. [Google Scholar] [CrossRef] [PubMed]
- Rojas-Giménez, M.; López-Medina, C.; Ladehesa-Pineda, M.L.; Puche-Larrubia, M.Á.; Gómez-García, I.; Calvo-Gutiérrez, J.; Seguí-Azpilcueta, P.; Ábalos-Aguilera, M.d.C.; Ruíz-Vilchez, D.; Escudero-Contreras, A.; et al. Subclinical Atherosclerosis Measure by Carotid Ultrasound and Inflammatory Activity in Patients with Rheumatoid Arthritis and Spondylarthritis. J. Clin. Med. 2022, 11, 662. [Google Scholar] [CrossRef] [PubMed]
- Bai, R.; Zhang, Y.; Liu, W.; Ma, C.; Chen, X.; Yang, J.; Sun, D. The Relationship of Ankylosing Spondylitis and Subclinical Atherosclerosis: A Systemic Review and Meta-Analysis. Angiology 2019, 70, 492–500. [Google Scholar] [CrossRef] [PubMed]
- Arida, A.; Protogerou, A.D.; Konstantonis, G.; Konsta, M.; Delicha, E.M.; Kitas, G.D.; Sfikakis, P.P. Subclinical Atherosclerosis Is Not Accelerated in Patients with Ankylosing Spondylitis with Low Disease Activity: New Data and Metaanalysis of Published Studies. J. Rheumatol. 2015, 42, 2098–2105. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Juanatey, C.; Llorca, J.; Amigo-Diaz, E.; Dierssen, T.; Martin, J.; Gonzalez-Gay, M.A. High prevalence of subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease or classic atherosclerosis risk factors. Arthritis Rheum. 2007, 57, 1074–1080. [Google Scholar] [CrossRef] [PubMed]
- Tam, L.; Shang, Q.; Li, E.K.; Tomlinson, B.; Chu, T.T.W.; Li, M.; Leung, Y.; Kwok, L.; Wong, K.; Li, T.K.; et al. Subclinical carotid atherosclerosis in patients with psoriatic arthritis. Arthritis Rheum. 2008, 59, 1322–1331. [Google Scholar] [CrossRef] [PubMed]
- Kerekes, G.; Soltész, P.; Nurmohamed, M.T.; Gonzalez-Gay, M.A.; Turiel, M.; Végh, E.; Shoenfeld, Y.; McInnes, I.; Szekanecz, Z. Validated methods for assessment of subclinical atherosclerosis in rheumatology. Nat. Rev. Rheumatol. 2012, 8, 224–234. [Google Scholar] [CrossRef] [PubMed]
- Jesson, C.; Bohbot, Y.; Soudet, S.; Renard, C.; Sobhy Danial, J.M.; Diep, L.; Doussière, M.; Tribouilloy, C.; Goëb, V. Is the Calcium Score Useful for Rheumatoid Arthritis Patients at Low or Intermediate Cardiovascular Risk? J. Clin. Med. 2022, 11, 4841. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Aletaha, D.; Neogi, T.; Silman, A.J.; Funovits, J.; Felson, D.T.; Bingham, C.O., 3rd; Birnbaum, N.S.; Burmester, G.R.; Bykerk, V.P.; Cohen, M.D.; et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010, 62, 2569–2581. [Google Scholar] [CrossRef] [PubMed]
- Van Der Linden, S.; Valkenburg, H.A.; Cats, A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criterio. Arthritis Rheum. 1984, 27, 361–368. [Google Scholar] [CrossRef] [PubMed]
- Taylor, W.; Gladman, D.; Helliwell, P.; Marchesoni, A.; Mease, P.; Mielants, H.; CASPAR Study Group. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis Rheum. 2006, 54, 2665–2673. [Google Scholar] [CrossRef] [PubMed]
- López-Mejías, R.; Castañeda, S.; González-Juanatey, C.; Corrales, A.; Ferraz-Amaro, I.; Genre, F.; Remuzgo-Martínez, S.; Rodriguez-Rodriguez, L.; Blanco, R.; Llorca, J.; et al. Cardiovascular risk assessment in patients with rheumatoid arthritis: The relevance of clinical, genetic and serological markers. Autoimmun. Rev. 2016, 15, 1013–1030. [Google Scholar] [CrossRef] [PubMed]
- Aubry, M.-C.; Maradit-Kremers, H.; Reinalda, M.S.; Crowson, C.S.; Edwards, W.D.; Gabriel, S.E. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J. Rheumatol. 2007, 34, 937–942. [Google Scholar] [PubMed]
- Holmqvist, M.; Mantel, Ä.; Wållberg-Jonsson, S.; James, S.; Jernberg, T.; Askling, J. Findings on Coronary Angiographies in Patients With Rheumatoid Arthritis and Ischemic Heart Disease: Are They Different From Patients Without Rheumatoid Arthritis? Arthritis Care Res. 2021, 73, 658–665. [Google Scholar] [CrossRef] [PubMed]
- Hansen, P.R.; Feineis, M.; Abdulla, J. Rheumatoid arthritis patients have higher prevalence and burden of asymptomatic coronary artery disease assessed by coronary computed tomography: A systematic literature review and meta-analysis. Eur. J. Intern. Med. 2019, 62, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Ozdowska, P.; Wardziak, Ł.; Kruk, M.; Kępka, C.; Kowalik, I.; Szwed, H.; Głuszko, P.; Rupiński, R.; Kwiatkowska, B.; Sikorska-Siudek, K.; et al. Increased prevalence of subclinical coronary atherosclerosis in young patients with ankylosing spondylitis. Pol. Arch. Intern. Med. 2018, 128, 455–461. [Google Scholar] [CrossRef] [PubMed]
- A Karpouzas, G.; Malpeso, J.; Choi, T.-Y.; Li, D.; Munoz, S.; Budoff, M.J. Prevalence, extent and composition of coronary plaque in patients with rheumatoid arthritis without symptoms or prior diagnosis of coronary artery disease. Ann. Rheum. Dis. 2014, 73, 1797–1804. [Google Scholar] [CrossRef] [PubMed]
- Gonzalez-Gay, M.A.; Gonzalez-Juanatey, C.; Piñeiro, A.; Garcia-Porrua, C.; Testa, A.; Llorca, J. High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J. Rheumatol. 2005, 32, 1219–1223. [Google Scholar] [PubMed]
- Gonzalez-Gay, M.A.; Gonzalez-Juanatey, C.; Vazquez-Rodriguez, T.R.; Martin, J.; Llorca, J. Endothelial dysfunction, carotid intima-media thickness, and acceleratedatherosclerosis in rheumatoid arthritis. Semin. Arthritis Rheum. 2008, 38, 67–70. [Google Scholar] [CrossRef] [PubMed]
- Karpouzas, G.A.; Ormseth, S.R.; Hernandez, E.; Budoff, M.J. The impact of statins on coronary atherosclerosis progression and long-term cardiovascular disease risk in rheumatoid arthritis. Rheumatology 2022, 61, 1857–1866. [Google Scholar] [CrossRef] [PubMed]
- Faccini, A.; Kaski, J.C.; Camici, P.G. Coronary microvascular dysfunction in chronic inflammatory rheumatoid diseases. Eur. Heart J. 2016, 37, 1799–1806. [Google Scholar] [CrossRef] [PubMed]
- Geng, Y.; Wu, X.; Liu, H.; Zheng, D.; Xia, L. Index of microcirculatory resistance: State-of-the-art and potential applications in computational simulation of coronary artery disease. J. Zhejiang Univ. Sci. B 2022, 23, 123–140. [Google Scholar] [CrossRef] [PubMed] [PubMed Central]
- Agca, R.; Heslinga, S.C.; Rollefstad, S.; Heslinga, M.; McInnes, I.B.; Peters, M.J.L.; Kvien, T.K.; Dougados, M.; Radner, H.; Atzeni, F.; et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann. Rheum. Dis. 2017, 76, 17–28. [Google Scholar] [CrossRef] [PubMed]
- Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Atherosclerosis 2019, 290, 140–205, Erratum in Atherosclerosis 2020, 292, 160–162. Erratum in Atherosclerosis 2020, 294, 80–82. [Google Scholar] [CrossRef] [PubMed]
- Mach, F.; Baigent, C.; Catapano, A.L.; Koskinas, K.C.; Casula, M.; Badimon, L.; Chapman, M.J.; De Backer, G.G.; Delgado, V.; Ference, B.A.; et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. Eur. Heart J. 2020, 41, 111–188. [Google Scholar] [CrossRef] [PubMed]
Variable | CIRD | Non-CIRD | p |
---|---|---|---|
Age (mean ± SD) | 66.9 ± 11.2 | 66.8 ± 11.5 | 0.95 |
Age (median, IQR) | 66.6 (58.3, 75.2) | 66.3 (58.1, 75.8) | |
Gender (men/women) | 42 (63.6%)/24 | 89 (63.6%)/51 | 0.99 |
Number of coronary arteries affected | 2.03 ± 1.32 | 1.56 ± 1.45 | 0.03 |
Coronary Artery | CIRD * | Non-CIRD ** | Odds Ratio (95% CI) | p | Area Under the ROC Curve (95% CI) |
---|---|---|---|---|---|
Left heart dominance | 6/66 | 9/140 | 1.46 (0.41, 4.81) | 0.49 | 0.514 (0.473, 0.554) |
Left main coronary artery | 6/65 | 18/140 | 0.69 (0.21, 1.94) | 0.45 | 0.482 (0.437, 0.527) |
Proximal anterior Descending artery | 20/66 | 27/140 | 1.82 (0.87, 3.75) | 0.08 | 0.555 (0.490, 0.620) |
Mid anterior descending artery | 37/66 | 48/140 | 2.45 (1.29, 4.65) | 0.003 | 0.609 (0.537, 0.681) |
Diagonal artery | 13/66 | 25/140 | 1.13 (0.49, 2.50) | 0.75 | 0.509 (0.451, 0.567) |
Proximal circumflex artery | 10/66 | 24/140 | 0.86 (0.34 2.03) | 0.72 | 0.490 (0.436, 0.544) |
Left marginal artery (obtuse) | 10/66 | 22/140 | 0.96 (0.38, 2.28) | 0.92 | 0.497 (0.444, 0.550) |
Mid-distal circumflex artery | 7/66 | 12/140 | 1.27 (0.40, 3.69) | 0.64 | 0.510 (0.466, 0.554) |
Proximal-mid right coronary artery | 27/66 | 49/140 | 1.29 (0.67, 2.44) | 0.41 | 0.530 (0.458, 0.601) |
Right posterior descending | 9/66 | 6/140 | 3.53 (1.06, 12.5) | 0.02 | 0.547 (0.502, 0.592) |
Posterolateral artery | 1/66 | 5/140 | 0.42 (0.01, 3.83) | 0.41 | 0.490 (0.468, 0.511) |
CIRD * | Non-CIRD ** | Odds Ratio (95% CI) | p | Area Under the ROC Curve (95% CI) | |
---|---|---|---|---|---|
Coronary calcification | 5/66 | 3/140 | 3.74 (0.70, 24.7) | 0.06 | 0.527 (0.493, 0.562) |
Arterial thrombus | 1/66 | 6/140 | 0.34 (0.01, 2.93) | 0.31 | 0.486 (0.464, 0.509) |
Coronary ectasia or aneurysm | 6/66 | 7/140 | 1.90 (0.50, 6.90) | 0.26 | 0.521 (0.481, 0.560) |
Performed Revascularization | 50/66 | 85/140 | 2.02 (1.01, 4.18) | 0.03 | 0.587 (0.517, 0.657) |
No-reflow | 2/66 | 0/140 | --- | --- | 0.515 (0.494, 0.536) |
Coronary Artery | Rheumatoid Arthritis * | Ankylosing Spondylitis * | Psoriatic Arthritis * | p ** |
---|---|---|---|---|
Left heart dominance | 4/41 | 1/14 | 0/11 | 0.35 |
Left main coronary artery | 4/41 | 0/14 | 2/11 | 0.30 |
Proximal anterior Descending artery | 16/41 | 2/14 | 2/11 | 0.15 |
Mid anterior descending artery | 25/41 | 7/14 | 5/11 | 0.60 |
Diagonal artery | 8/41 | 1/14 | 4/11 | 0.20 |
Proximal circumflex artery | 8/41 | 1/14 | 1/11 | 0.55 |
Left marginal artery (obtuse) | 8/41 | 1/14 | 1/11 | 0.55 |
Mid-distal circumflex artery | 0/41 | 3/14 | 4/11 | <0.001 |
Proximal-mid right coronary artery | 16/41 | 5/14 | 6/11 | 0.64 |
Right posterior descending | 4/41 | 2/14 | 3/11 | 0.31 |
Posterolateral artery | 0/41 | 1/14 | 0/11 | 0.38 |
Coronary calcification | 4/41 | 0/14 | 1/11 | 0.66 |
Arterial thrombus | 0/41 | 0/14 | 1/11 | 0.17 |
Coronary ectasia or aneurysm | 3/41 | 2/14 | 1/11 | 0.83 |
Performed Revascularization | 31/41 | 10/14 | 9/11 | 0.89 |
No-reflow | 2/41 | 0/14 | 0/11 | 1.00 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Heras-Recuero, E.; Martínez-López, J.A.; Garbayo-Bugeda, M.; Castrillo-Capilla, Á.; Blázquez-Sánchez, T.; Torres-Roselló, A.; García-Fernández, A.; Llorca, J.; Largo, R.; Franco-Peláez, J.A.; et al. Identification of Coronary Morphological Damage in Patients with Chronic Inflammatory Rheumatic Diseases. Diagnostics 2025, 15, 922. https://doi.org/10.3390/diagnostics15070922
Heras-Recuero E, Martínez-López JA, Garbayo-Bugeda M, Castrillo-Capilla Á, Blázquez-Sánchez T, Torres-Roselló A, García-Fernández A, Llorca J, Largo R, Franco-Peláez JA, et al. Identification of Coronary Morphological Damage in Patients with Chronic Inflammatory Rheumatic Diseases. Diagnostics. 2025; 15(7):922. https://doi.org/10.3390/diagnostics15070922
Chicago/Turabian StyleHeras-Recuero, Elena, Juan Antonio Martínez-López, Macarena Garbayo-Bugeda, Álvaro Castrillo-Capilla, Teresa Blázquez-Sánchez, Arantxa Torres-Roselló, Antia García-Fernández, Javier Llorca, Raquel Largo, Juan Antonio Franco-Peláez, and et al. 2025. "Identification of Coronary Morphological Damage in Patients with Chronic Inflammatory Rheumatic Diseases" Diagnostics 15, no. 7: 922. https://doi.org/10.3390/diagnostics15070922
APA StyleHeras-Recuero, E., Martínez-López, J. A., Garbayo-Bugeda, M., Castrillo-Capilla, Á., Blázquez-Sánchez, T., Torres-Roselló, A., García-Fernández, A., Llorca, J., Largo, R., Franco-Peláez, J. A., Tuñón, J., & González-Gay, M. Á. (2025). Identification of Coronary Morphological Damage in Patients with Chronic Inflammatory Rheumatic Diseases. Diagnostics, 15(7), 922. https://doi.org/10.3390/diagnostics15070922